Literature DB >> 18272388

Oligodendroglioma.

Martin J Van den Bent1, Michele Reni, Gemma Gatta, Charles Vecht.   

Abstract

Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.

Entities:  

Mesh:

Year:  2008        PMID: 18272388     DOI: 10.1016/j.critrevonc.2007.11.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  21 in total

1.  Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging.

Authors:  M Zulfiqar; N Dumrongpisutikul; J Intrapiromkul; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

2.  Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Authors:  Gabrielle Truitt; Haley Gittleman; Rebecca Leece; Quinn T Ostrom; Carol Kruchko; Terri S Armstrong; Mark R Gilbert; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2019-06-17       Impact factor: 4.130

3.  Gene expression in oligodendroglial tumors.

Authors:  Elisabeth J Shaw; Brian Haylock; David Husband; Daniel du Plessis; D Ross Sibson; Peter C Warnke; Carol Walker
Journal:  Cell Oncol (Dordr)       Date:  2011-05-31       Impact factor: 6.730

4.  A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.

Authors:  Hui K Gan; Mark A Rosenthal; Anthony Dowling; Renate Kalnins; Elizabeth Algar; Nicholas Wong; Angela Benson; Anne-Marie Woods; Lawrence Cher
Journal:  Neuro Oncol       Date:  2010-02-08       Impact factor: 12.300

Review 5.  Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Authors:  Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2017-04-24       Impact factor: 4.130

6.  Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report.

Authors:  Yuan Jian; Wen Gao; Yin Wu; Yanchen Li; Yong Zhang; Guangzhong Yang; Wenming Chen
Journal:  Oncol Lett       Date:  2016-05-13       Impact factor: 2.967

Review 7.  The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors.

Authors:  Erin M Dunbar
Journal:  Curr Treat Options Oncol       Date:  2009-04-18

8.  TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Authors:  Aden Ka-Yin Chan; Yu Yao; Zhenyu Zhang; Nellie Yuk-Fei Chung; Joseph Shu-Ming Liu; Kay Ka-Wai Li; Zhifeng Shi; Danny Tat-Ming Chan; Wai Sang Poon; Liangfu Zhou; Ho-Keung Ng
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

9.  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals.

Authors:  Yan-Xi Li; Abudumijiti Aibaidula; Zhifeng Shi; Hong Chen; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Ryan Rui Yang; Danny Tat-Ming Chan; Wai Sang Poon; Ka Lok Ryan Lee; Ying Mao; Jinsong Wu; Aden Ka-Yin Chan; Liangfu Zhou; Ho-Keung Ng
Journal:  J Neurooncol       Date:  2018-05-14       Impact factor: 4.130

10.  Efficacy of anti-epileptic drugs in patients with gliomas and seizures.

Authors:  Mèlanie S M van Breemen; R M Rijsman; M J B Taphoorn; R Walchenbach; H Zwinkels; Charles J Vecht
Journal:  J Neurol       Date:  2009-05-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.